addressing an evolving drug safety landscape - moving from passive to active pharmacovigilance
TRANSCRIPT
![Page 1: Addressing an Evolving Drug Safety Landscape - Moving from passive to active pharmacovigilance](https://reader031.vdocuments.site/reader031/viewer/2022030312/58edf33a1a28abe92d8b460b/html5/thumbnails/1.jpg)
![Page 2: Addressing an Evolving Drug Safety Landscape - Moving from passive to active pharmacovigilance](https://reader031.vdocuments.site/reader031/viewer/2022030312/58edf33a1a28abe92d8b460b/html5/thumbnails/2.jpg)
•
•
•
•
•
•
![Page 3: Addressing an Evolving Drug Safety Landscape - Moving from passive to active pharmacovigilance](https://reader031.vdocuments.site/reader031/viewer/2022030312/58edf33a1a28abe92d8b460b/html5/thumbnails/3.jpg)
•
•
•
•
•
•
•
•
•
![Page 4: Addressing an Evolving Drug Safety Landscape - Moving from passive to active pharmacovigilance](https://reader031.vdocuments.site/reader031/viewer/2022030312/58edf33a1a28abe92d8b460b/html5/thumbnails/4.jpg)
•
•
•
![Page 5: Addressing an Evolving Drug Safety Landscape - Moving from passive to active pharmacovigilance](https://reader031.vdocuments.site/reader031/viewer/2022030312/58edf33a1a28abe92d8b460b/html5/thumbnails/5.jpg)
•
•0%
20%
40%
60%
80%
100%
Manufacturersubmitted -Expedited
reports
Manufacturersubmitted -
Periodicreports
Direct reportsby HCPs &
Patients
Incompletereports
Completereports
![Page 6: Addressing an Evolving Drug Safety Landscape - Moving from passive to active pharmacovigilance](https://reader031.vdocuments.site/reader031/viewer/2022030312/58edf33a1a28abe92d8b460b/html5/thumbnails/6.jpg)
![Page 7: Addressing an Evolving Drug Safety Landscape - Moving from passive to active pharmacovigilance](https://reader031.vdocuments.site/reader031/viewer/2022030312/58edf33a1a28abe92d8b460b/html5/thumbnails/7.jpg)
2% 3% 1%
11%
![Page 8: Addressing an Evolving Drug Safety Landscape - Moving from passive to active pharmacovigilance](https://reader031.vdocuments.site/reader031/viewer/2022030312/58edf33a1a28abe92d8b460b/html5/thumbnails/8.jpg)
15%
5%
32%
4% 6%
5%
9%
12%
12%
![Page 9: Addressing an Evolving Drug Safety Landscape - Moving from passive to active pharmacovigilance](https://reader031.vdocuments.site/reader031/viewer/2022030312/58edf33a1a28abe92d8b460b/html5/thumbnails/9.jpg)
•
•
•
•
•
•
![Page 10: Addressing an Evolving Drug Safety Landscape - Moving from passive to active pharmacovigilance](https://reader031.vdocuments.site/reader031/viewer/2022030312/58edf33a1a28abe92d8b460b/html5/thumbnails/10.jpg)
![Page 11: Addressing an Evolving Drug Safety Landscape - Moving from passive to active pharmacovigilance](https://reader031.vdocuments.site/reader031/viewer/2022030312/58edf33a1a28abe92d8b460b/html5/thumbnails/11.jpg)
.
![Page 12: Addressing an Evolving Drug Safety Landscape - Moving from passive to active pharmacovigilance](https://reader031.vdocuments.site/reader031/viewer/2022030312/58edf33a1a28abe92d8b460b/html5/thumbnails/12.jpg)
![Page 13: Addressing an Evolving Drug Safety Landscape - Moving from passive to active pharmacovigilance](https://reader031.vdocuments.site/reader031/viewer/2022030312/58edf33a1a28abe92d8b460b/html5/thumbnails/13.jpg)
![Page 14: Addressing an Evolving Drug Safety Landscape - Moving from passive to active pharmacovigilance](https://reader031.vdocuments.site/reader031/viewer/2022030312/58edf33a1a28abe92d8b460b/html5/thumbnails/14.jpg)
•
•
•
•
•
•
•
•
•
•
•
![Page 15: Addressing an Evolving Drug Safety Landscape - Moving from passive to active pharmacovigilance](https://reader031.vdocuments.site/reader031/viewer/2022030312/58edf33a1a28abe92d8b460b/html5/thumbnails/15.jpg)
![Page 16: Addressing an Evolving Drug Safety Landscape - Moving from passive to active pharmacovigilance](https://reader031.vdocuments.site/reader031/viewer/2022030312/58edf33a1a28abe92d8b460b/html5/thumbnails/16.jpg)
![Page 17: Addressing an Evolving Drug Safety Landscape - Moving from passive to active pharmacovigilance](https://reader031.vdocuments.site/reader031/viewer/2022030312/58edf33a1a28abe92d8b460b/html5/thumbnails/17.jpg)
•
•
•
![Page 18: Addressing an Evolving Drug Safety Landscape - Moving from passive to active pharmacovigilance](https://reader031.vdocuments.site/reader031/viewer/2022030312/58edf33a1a28abe92d8b460b/html5/thumbnails/18.jpg)
•
•
•
![Page 19: Addressing an Evolving Drug Safety Landscape - Moving from passive to active pharmacovigilance](https://reader031.vdocuments.site/reader031/viewer/2022030312/58edf33a1a28abe92d8b460b/html5/thumbnails/19.jpg)
•
•
•
![Page 20: Addressing an Evolving Drug Safety Landscape - Moving from passive to active pharmacovigilance](https://reader031.vdocuments.site/reader031/viewer/2022030312/58edf33a1a28abe92d8b460b/html5/thumbnails/20.jpg)
•
•
•